Title:Targeting the LKB1 Tumor Suppressor
Volume: 15
Issue: 1
Author(s): Rui-Xun Zhao and Zhi-Xiang Xu
Affiliation:
Keywords:
LKB1 (serine-threonine kinase 11, STK11), AMP-activated protein kinase (AMPK), tumor suppression, mutations,
targeting therapeutics.
Abstract: LKB1 (also known as serine-threonine kinase 11, STK11) is a tumor suppressor, which is mutated or deleted in
Peutz-Jeghers syndrome (PJS) and in a variety of cancers. Physiologically, LKB1 possesses multiple cellular functions in
the regulation of cell bioenergetics metabolism, cell cycle arrest, embryo development, cell polarity, and apoptosis. New
studies demonstrated that LKB1 may also play a role in the maintenance of function and dynamics of hematopoietic stem
cells. Over the past years, personalized therapy targeting specific genetic aberrations has attracted intense interests. Within
this review, several agents with potential activity against aberrant LKB1 signaling have been discussed. Potential strategies
and challenges in targeting LKB1 inactivation are also considered.
